ClinicalTrials.gg
CompletedNCT02159352Updated Nov 30, 2015Results posted

Study Assessing the Effects of Darunavir/Ritonavir or Lopinavir/Ritonavir on the Pharmacokinetics of Daclatasvir in Healthy Participants

A Phase 1 interventional study of Daclatasvir and Darunavir in Hepatitis C, sponsored by Bristol-Myers Squibb. Completed at 1 site in United States. Open to participants aged 18 Years to 49 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2015-11-30.

Sponsored by Bristol-Myers Squibb · Phase 1 and Interventional

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
49
Allocation
Randomized
Ages
18 Years to 49 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 59 studies testing daclatasvir in Hepatitis C — 1 open to participants now, 2 under way, 1 of them phase 3. daclatasvir · Hepatitis C.

Enrollment
42nd of 59
49 · median 100
Started
2014
with 12 others
Phase 1
10 of 59
none open now
Registered
36th of 59
by date
Lead sponsor
42 of 59
Bristol-Myers Squibb

Among the 59 studies testing daclatasvir in Hepatitis C, this one is the 42nd largest by enrollment, is one of 13 that started in 2014, is one of 10 in phase 1, and was the 36th registered.

Hepatitis C

1,744 studies on the registry are indexed under Hepatitis C; 98 are open to participants now.

Browse Hepatitis C studies →

Open to participants now

1 of the 59 studies testing daclatasvir in Hepatitis C is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About daclatasvir

daclatasvir: first FDA approval 2015 (DAKLINZA), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 56 Hepatitis C studies recruiting now, 43 (77%) set no upper age limit and 6 (11%) stop at 75 or younger; 10 take children under 18; 26 take healthy volunteers.

This study: 18 Years to 49 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 59 studies testing daclatasvir in Hepatitis C, or all of them as a file.
02

Study summary

The purpose of this study is to determine whether multiple doses of darunavir/ritonavir or lopinavir/ritonavir affect the pharmacokinetics of daclatasvir in healthy participants.

03

Conditions studied

  • Hepatitis C

Browse trials for

04

Who can participate

Ages eligible
18 Years to 49 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com

Key Inclusion Criteria:

  • Healthy male and female participants, aged 18 to 49, as determined by medical history, physical examination, 12 lead , vital signs, and clinical laboratory evaluations

Key Exclusion Criteria:

  • Any significant acute or chronic medical illness; donation of blood to a blood bank or in a clinical study (except a screening visit) within 4 weeks of study drug administration (within 2 weeks for plasma only); or blood screen findings positive for antibody, surface antigen, or -1 and HIV-2 antibodies
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
49 participants (actual)

Study arms

  • Experimental
    Group 1: Daclatasvir and Darunavir/Ritonavir

    Treatment A: Daclatasvir oral tablet on specific days Treatment B: Daclatasvir tablet and Darunavir Tablet/Ritonavir capsule orally on specific days

    Drug: Daclatasvir · Drug: Darunavir · Drug: Ritonavir

  • Experimental
    Group 2: Daclatasvir and Lopinavir/Ritonavir

    Treatment C: Daclatasvir oral tablet on specific days Treatment D: Daclatasvir tablet and Lopinavir/Ritonavir tablet orally on specific days

    Drug: Daclatasvir · Drug: Ritonavir · Drug: Lopinavir/Ritonavir

Interventions

06

What researchers measure

Primary outcomes

  1. Maximum Observed Plasma Concentration (Cmax) for Daclatasvir

    Cmax was obtained from concentration-time plot using a noncompartmental method and a validated pharmacokinetic analysis program.

    Time frame: Predose (0 hour) on Day 2, 3 and 0, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24 hours on Day 4 (Period 1); Predose (0 hour) on Day 12, 13 and 0, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24 hour on Day 14 (Period 2)

  2. Area Under the Concentration-Time Curve in 1 Dosing Interval (AUC[TAU]) for Daclatasvir

    AUC(TAU) was the area under the curve from time zero to end of dosing interval. AUC(TAU) was obtained from concentration-time plot of daclatasvir using noncompartmental method and a validated pharmacokinetic analysis program.

    Time frame: Predose (0 hour) on Day 2, 3 and 0, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24 hours on Day 4 (Period 1); Predose (0 hour) on Day 12, 13 and 0, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24 hour on Day 14 (Period 2)

Secondary outcomes

  1. Time of Maximum Observed Plasma Concentration (Tmax) of Daclatasvir

    Tmax was obtained from concentration-time plot of daclatasvir by using non-compartmental method by a validated pharmacokinetic analysis program.

    Time frame: Predose (0 hour) on Day 2, 3 and 0, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24 hours on Day 4 (Period 1); Predose (0 hour) on Day 12, 13 and 0, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24 hour on Day 14 (Period 2)

  2. Plasma Concentration Observed at 24 Hours Postdose (C24) of Daclatasvir

    C24 was obtained from concentration time plot of daclatasvir by using noncompartmental method by a validated pharmacokinetic analysis program.

    Time frame: Predose (0 hour) on Day 2, 3 and 0, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24 hours on Day 4 (Period 1); Predose (0 hour) on Day 12, 13 and 0, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24 hour on Day 14 (Period 2)

  3. Dose-normalized Maximum Observed Plasma Concentration (Cmax/D) and Dose-normalized Plasma Concentration Observed at 24 Hours Postdose (C24/D) of Daclatasvir

    Cmax/D and C24/D are obtained from concentration-time plot of daclatasvir by using noncompartmental method by a validated pharmacokinetic analysis program.

    Time frame: Predose (0 hour) on Day 2, 3 and 0, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24 hours on Day 4 (Period 1); Predose (0 hour) on Day 12, 13 and 0, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24 hour on Day 14 (Period 2)

  4. Dose-normalized Area Under the Concentration-Time Curve in 1 Dosing Interval (AUC[TAU]/D) of Daclatasvir

    AUC(TAU)/D was obtained from concentration-time plot of daclatasvir by using noncompartmental method by a validated pharmacokinetic analysis program.

    Time frame: Predose (0 hour) on Day 2, 3 and 0, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24 hours on Day 4 (Period 1); Predose (0 hour) on Day 12, 13 and 0, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24 hour on Day 14 (Period 2)

  5. Number of Participants With Serious Adverse Events (SAEs) and Discontinuations Due to Adverse Events (AEs) and Who Died

    AE was defined as any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that does not necessarily have a causal relationship with treatment. SAE was defined as a medical event that at any dose resulted in death, persistent or significant disability/incapacity, or drug dependency/abuse; was life threatening, an important medical event, or a congenital anomaly/birth defect; or required or prolonged hospitalization.

    Time frame: From start of study treatment (Day 1) to study discharge for AEs (up to 15 days); Day 1 to 30 days after last dose of study treatment for SAEs (up to 44 days)

  6. Number of Participants With Abnormalities in Vital Sign Measurements

    Criteria for abnormalities in vital sign measurements: Diastolic blood pressure: Value \>90 and change from baseline \> 0 or value \< 55 and change from baseline \<-10. Systolic blood pressure: Value \>140 and change from baseline \>20 or value \<90 and change from baseline \<-20. Heart rate: Value \>100 and change from baseline \>30 or value \<55 and change from baseline \<-15. Respiration: Value \>16 or change from baseline \>10. Temperature: Value \>38.3°C or change from baseline \>1.6°C.

    Time frame: From start of study treatment (Day 1) to study discharge (up to 15 days)

  7. Number of Participants With Abnormalities in Electrocardiogram (ECG) Findings

    Abnormalities in ECG findings included: PR ≥210 msec, QRS ≥120 msec, QT ≥500 msec, QTcF ≥450 msec, and second- or third-degree heart block.

    Time frame: From start of study treatment (Day 1) to study discharge (up to 15 days)

  8. Number of Participants With Marked Abnormalities in Hematology Laboratory Test Results

    Criteria for marked abnormalities in test results: Platelet count \>1.5\*upper limits of normal (ULN) value, \>1.5\*ULN if pretreatment (PreRx) value is missing, \<0.85\*lower limit of normal (LLN) if PreRx ≥LLN, \<0.85\*LLN if PreRx is missing, \<0.85\*PreRx if PreRx \<LLN. Leukocytes \>1.2\*ULN if LLN ≤PreRx ≤ULN, \>1.2\*ULN if PreRx is missing, \>1.5\*PreRx if PreRx \>ULN, \>ULN if PreRx \<LLN, \<0.85\*PreRx if PreRx \<LLN, \<0.9\*LLN if LLN ≤PreRx ≤ULN, \<0.9\*LLN if PreRx is missing and \<LLN if PreRx \>ULN. Lymphocytes \>7.5\*10\^3 c/uL and \<0.75\*10\^3 c/uL. Neutrophils \<0.85\*PreRx if PreRx \<1.5\*ULN, \<1.5\*ULN if PreRx ≥1.5\*ULN and \<1.5\*ULN if PreRx is missing.

    Time frame: From start of study treatment (Day 1) to study discharge (up to 15 days)

  9. Number of Participants With Abnormalities in Urinalysis and Other Chemistry Testing Results

    Criteria for marked abnormalities on laboratory test results: urinary dipstick blood: ≥2 if pretreatment (PreRx) \<1, ≥2 if PreRx is missing or ≥2\*PreRx if PreRx ≥1. Urinary microscopic red blood cell (RBC): ≥2 if PreRx \<2, ≥2 if PreRx is missing or ≥4 if PreRx ≥2. Urinary microscopic white blood cell (WBC): ≥2 if PreRx \<2, ≥2 if PreRx is missing or ≥4 if PreRx ≥2. Lactate dehydrogenase \>1.25\*upper limit of normal (ULN) if PreRx ≤ULN, \>1.25\*ULN if PreRx is missing and \>1.5\*PreRx if PreRx \>ULN.

    Time frame: From start of study treatment (Day 1) to study discharge (up to 15 days)

07

Results

Posted Nov 30, 2015

Participant flow

Participants were enrolled at 1 site in the United States of America.

Participant flow — Overall Study
MilestoneDaclatasvir + Darunavir/RitonavirDaclatasvir + Lopinavir/Ritonavir
Started1414
Phase 1 (day 1- 4)1414
Phase 2 (day 5-14)1112
Completed1112
Not completed32
Withdrew: Adverse event31
Withdrew: Withdrawal by subject01

Outcome measures

PrimaryMaximum Observed Plasma Concentration (Cmax) for Daclatasvir

Cmax was obtained from concentration-time plot using a noncompartmental method and a validated pharmacokinetic analysis program.

Time frame:
Predose (0 hour) on Day 2, 3 and 0, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24 hours on Day 4 (Period 1); Predose (0 hour) on Day 12, 13 and 0, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24 hour on Day 14 (Period 2)
Reported as:
Geometric mean · ng/mL
Maximum Observed Plasma Concentration (Cmax) for Daclatasvir
ng/mLGroup 1: Daclatasvir (60 mg)Group 1: Daclatasvir (30 mg) + Darunavir/RitonavirGroup 2: Daclatasvir (60 mg)Group 2: Daclatasvir (30 mg) + Lopinavir/Ritonavir
Maximum Observed Plasma Concentration (Cmax) for Daclatasvir1335 ± 38493 ± 361412 ± 28476 ± 21
Statistical analysis
  • Group 1: Daclatasvir (60 mg) vs Group 1: Daclatasvir (30 mg) + Darunavir/Ritonavir · Adjusted geometric mean ratio: 0.384 · 90% CI 0.348 to 0.423
  • Group 2: Daclatasvir (60 mg) vs Group 2: Daclatasvir (30 mg) + Lopinavir/Ritonavir · Adjusted geometric mean ratio: 0.337 · 90% CI 0.306 to 0.371
PrimaryArea Under the Concentration-Time Curve in 1 Dosing Interval (AUC[TAU]) for Daclatasvir

AUC(TAU) was the area under the curve from time zero to end of dosing interval. AUC(TAU) was obtained from concentration-time plot of daclatasvir using noncompartmental method and a validated pharmacokinetic analysis program.

Time frame:
Predose (0 hour) on Day 2, 3 and 0, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24 hours on Day 4 (Period 1); Predose (0 hour) on Day 12, 13 and 0, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24 hour on Day 14 (Period 2)
Reported as:
Geometric mean · ng*h/mL
Area Under the Concentration-Time Curve in 1 Dosing Interval (AUC[TAU]) for Daclatasvir
ng*h/mLDaclatasvir (60 mg) Days 1-4Daclatasvir (30 mg) + Darunavir/Ritonavir Days 5-14Daclatasvir (60 mg) Days 5-14Daclatasvir (30 mg) + Lopinavir/Ritonavir Days 5-14
Area Under the Concentration-Time Curve in 1 Dosing Interval (AUC[TAU]) for Daclatasvir12677 ± 418295 ± 3913799 ± 267855 ± 23
Statistical analysis
  • Daclatasvir (60 mg) Days 1-4 vs Daclatasvir (30 mg) + Darunavir/Ritonavir Days 5-14 · Adjusted geometric mean ratio: 0.703 · 90% CI 0.658 to 0.750
  • Daclatasvir (60 mg) Days 5-14 vs Daclatasvir (30 mg) + Lopinavir/Ritonavir Days 5-14 · Adjusted geometric mean ratio: 0.577 · 90% CI 0.535 to 0.622
SecondaryTime of Maximum Observed Plasma Concentration (Tmax) of Daclatasvir

Tmax was obtained from concentration-time plot of daclatasvir by using non-compartmental method by a validated pharmacokinetic analysis program.

Time frame:
Predose (0 hour) on Day 2, 3 and 0, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24 hours on Day 4 (Period 1); Predose (0 hour) on Day 12, 13 and 0, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24 hour on Day 14 (Period 2)
Reported as:
Median · hours
Time of Maximum Observed Plasma Concentration (Tmax) of Daclatasvir
hoursGroup 1: Daclatasvir (60 mg)Group 1: Daclatasvir (30 mg) + Darunavir/RitonavirGroup 2: Daclatasvir (60 mg)Group 2: Daclatasvir (30 mg) + Lopinavir/Ritonavir
Time of Maximum Observed Plasma Concentration (Tmax) of Daclatasvir2.00 (1.00 to 6.00)3.00 (1.00 to 6.00)2.00 (1.00 to 6.00)2.00 (1.00 to 11.93)
SecondaryPlasma Concentration Observed at 24 Hours Postdose (C24) of Daclatasvir

C24 was obtained from concentration time plot of daclatasvir by using noncompartmental method by a validated pharmacokinetic analysis program.

Time frame:
Predose (0 hour) on Day 2, 3 and 0, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24 hours on Day 4 (Period 1); Predose (0 hour) on Day 12, 13 and 0, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24 hour on Day 14 (Period 2)
Reported as:
Geometric mean · ng/mL
Plasma Concentration Observed at 24 Hours Postdose (C24) of Daclatasvir
ng/mLGroup 1: Daclatasvir (60 mg)Group 1: Daclatasvir (30 mg) + Darunavir/RitonavirGroup 2: Daclatasvir (60 mg)Group 2: Daclatasvir (30 mg) + Lopinavir/Ritonavir
Plasma Concentration Observed at 24 Hours Postdose (C24) of Daclatasvir225 ± 54250 ± 45225 ± 36280 ± 29
SecondaryDose-normalized Maximum Observed Plasma Concentration (Cmax/D) and Dose-normalized Plasma Concentration Observed at 24 Hours Postdose (C24/D) of Daclatasvir

Cmax/D and C24/D are obtained from concentration-time plot of daclatasvir by using noncompartmental method by a validated pharmacokinetic analysis program.

Time frame:
Predose (0 hour) on Day 2, 3 and 0, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24 hours on Day 4 (Period 1); Predose (0 hour) on Day 12, 13 and 0, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24 hour on Day 14 (Period 2)
Reported as:
Geometric mean · ng/mL/mg
Dose-normalized Maximum Observed Plasma Concentration (Cmax/D) and Dose-normalized Plasma Concentration Observed at 24 Hours Postdose (C24/D) of Daclatasvir
ng/mL/mgGroup 1: Daclatasvir (60 mg)Group 1: Daclatasvir (30 mg) + Darunavir/RitonavirGroup 2: Daclatasvir (60 mg)Group 2: Daclatasvir (30 mg) + Lopinavir/Ritonavir
Cmax/D22.2 ± 3816.4 ± 3623.5 ± 2815.9 ± 21
C24/D3.75 ± 548.34 ± 453.76 ± 369.33 ± 29
Statistical analysis
  • Group 1: Daclatasvir (60 mg) vs Group 1: Daclatasvir (30 mg) + Darunavir/Ritonavir · Adjusted geometric mean ratio: 0.768 · 90% CI 0.697 to 0.846
  • Group 2: Daclatasvir (60 mg) vs Group 2: Daclatasvir (30 mg) + Lopinavir/Ritonavir · Adjusted geometric mean ratio: 0.673 · 90% CI 0.611 to 0.742
SecondaryDose-normalized Area Under the Concentration-Time Curve in 1 Dosing Interval (AUC[TAU]/D) of Daclatasvir

AUC(TAU)/D was obtained from concentration-time plot of daclatasvir by using noncompartmental method by a validated pharmacokinetic analysis program.

Time frame:
Predose (0 hour) on Day 2, 3 and 0, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24 hours on Day 4 (Period 1); Predose (0 hour) on Day 12, 13 and 0, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24 hour on Day 14 (Period 2)
Reported as:
Geometric mean · (ng*h/mL)/mg
Dose-normalized Area Under the Concentration-Time Curve in 1 Dosing Interval (AUC[TAU]/D) of Daclatasvir
(ng*h/mL)/mgGroup 1: Daclatasvir (60 mg)Group 1: Daclatasvir (30 mg) + Darunavir/RitonavirGroup 2: Daclatasvir (60 mg)Group 2: Daclatasvir (30 mg) + Lopinavir/Ritonavir
Dose-normalized Area Under the Concentration-Time Curve in 1 Dosing Interval (AUC[TAU]/D) of Daclatasvir211 ± 41276 ± 39230 ± 26262 ± 23
Statistical analysis
  • Group 1: Daclatasvir (60 mg) vs Group 1: Daclatasvir (30 mg) + Darunavir/Ritonavir · Adjusted geometric mean ratio: 1.406 · 90% CI 1.317 to 1.501
  • Group 2: Daclatasvir (60 mg) vs Group 2: Daclatasvir (30 mg) + Lopinavir/Ritonavir · Adjusted geometric mean ratio: 1.154 · 90% CI 1.070 to 1.244
SecondaryNumber of Participants With Serious Adverse Events (SAEs) and Discontinuations Due to Adverse Events (AEs) and Who Died

AE was defined as any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that does not necessarily have a causal relationship with treatment. SAE was defined as a medical event that at any dose resulted in death, persistent or significant disability/incapacity, or drug dependency/abuse; was life threatening, an important medical event, or a congenital anomaly/birth defect; or required or prolonged hospitalization.

Time frame:
From start of study treatment (Day 1) to study discharge for AEs (up to 15 days); Day 1 to 30 days after last dose of study treatment for SAEs (up to 44 days)
Reported as:
Number · participants
Number of Participants With Serious Adverse Events (SAEs) and Discontinuations Due to Adverse Events (AEs) and Who Died
participantsGroup 1: Daclatasvir (60 mg)Group 1: Daclatasvir (30 mg) + Darunavir/RitonavirGroup 2: Daclatasvir (60 mg)Group 2: Daclatasvir (30 mg) + Lopinavir/Ritonavir
SAE0000
Discontinued due to AEs0301
Death0000
SecondaryNumber of Participants With Abnormalities in Vital Sign Measurements

Criteria for abnormalities in vital sign measurements: Diastolic blood pressure: Value \>90 and change from baseline \> 0 or value \< 55 and change from baseline \<-10. Systolic blood pressure: Value \>140 and change from baseline \>20 or value \<90 and change from baseline \<-20. Heart rate: Value \>100 and change from baseline \>30 or value \<55 and change from baseline \<-15. Respiration: Value \>16 or change from baseline \>10. Temperature: Value \>38.3°C or change from baseline \>1.6°C.

Time frame:
From start of study treatment (Day 1) to study discharge (up to 15 days)
Reported as:
Number · participants
Number of Participants With Abnormalities in Vital Sign Measurements
participantsGroup 1: Daclatasvir + Darunavir/RitonavirGroup 2: Daclatasvir + Lopinavir/Ritonavir
Number of Participants With Abnormalities in Vital Sign Measurements32
SecondaryNumber of Participants With Abnormalities in Electrocardiogram (ECG) Findings

Abnormalities in ECG findings included: PR ≥210 msec, QRS ≥120 msec, QT ≥500 msec, QTcF ≥450 msec, and second- or third-degree heart block.

Time frame:
From start of study treatment (Day 1) to study discharge (up to 15 days)
Reported as:
Number · participants
Number of Participants With Abnormalities in Electrocardiogram (ECG) Findings
participantsGroup 1: Daclatasvir (60 mg)Group 1: Daclatasvir (30 mg) + Darunavir/RitonavirGroup 2: Daclatasvir (60 mg)Group 2: Daclatasvir (30 mg) + Lopinavir/Ritonavir
PR >2102401
QRS >1200000
QT >5000000
QTcF >4500100
SecondaryNumber of Participants With Marked Abnormalities in Hematology Laboratory Test Results

Criteria for marked abnormalities in test results: Platelet count \>1.5\*upper limits of normal (ULN) value, \>1.5\*ULN if pretreatment (PreRx) value is missing, \<0.85\*lower limit of normal (LLN) if PreRx ≥LLN, \<0.85\*LLN if PreRx is missing, \<0.85\*PreRx if PreRx \<LLN. Leukocytes \>1.2\*ULN if LLN ≤PreRx ≤ULN, \>1.2\*ULN if PreRx is missing, \>1.5\*PreRx if PreRx \>ULN, \>ULN if PreRx \<LLN, \<0.85\*PreRx if PreRx \<LLN, \<0.9\*LLN if LLN ≤PreRx ≤ULN, \<0.9\*LLN if PreRx is missing and \<LLN if PreRx \>ULN. Lymphocytes \>7.5\*10\^3 c/uL and \<0.75\*10\^3 c/uL. Neutrophils \<0.85\*PreRx if PreRx \<1.5\*ULN, \<1.5\*ULN if PreRx ≥1.5\*ULN and \<1.5\*ULN if PreRx is missing.

Time frame:
From start of study treatment (Day 1) to study discharge (up to 15 days)
Reported as:
Number · participants
Number of Participants With Marked Abnormalities in Hematology Laboratory Test Results
participantsGroup 1: Daclatasvir (60 mg)Group 1: Daclatasvir (30 mg) + Darunavir/RitonavirGroup 2: Daclatasvir (60 mg)Group 2: Daclatasvir (30 mg) + Lopinavir/Ritonavir
Platelet Count1000
Leukocytes0111
Neutrophils (absolute)0210
Lymphocytes (absolute)0100
SecondaryNumber of Participants With Abnormalities in Urinalysis and Other Chemistry Testing Results

Criteria for marked abnormalities on laboratory test results: urinary dipstick blood: ≥2 if pretreatment (PreRx) \<1, ≥2 if PreRx is missing or ≥2\*PreRx if PreRx ≥1. Urinary microscopic red blood cell (RBC): ≥2 if PreRx \<2, ≥2 if PreRx is missing or ≥4 if PreRx ≥2. Urinary microscopic white blood cell (WBC): ≥2 if PreRx \<2, ≥2 if PreRx is missing or ≥4 if PreRx ≥2. Lactate dehydrogenase \>1.25\*upper limit of normal (ULN) if PreRx ≤ULN, \>1.25\*ULN if PreRx is missing and \>1.5\*PreRx if PreRx \>ULN.

Time frame:
From start of study treatment (Day 1) to study discharge (up to 15 days)
Reported as:
Number · participants
Number of Participants With Abnormalities in Urinalysis and Other Chemistry Testing Results
participantsGroup 1: Daclatasvir (60 mg)Group 1: Daclatasvir (30 mg) + Darunavir/RitonavirGroup 2: Daclatasvir (60 mg)Group 2: Daclatasvir (30 mg) + Lopinavir/Ritonavir
Blood, urine2110
RBC, urine1100
WBC, urine1300
Lactate dehydrogenase2211

Adverse events

Collected over From start of study treatment (Day 1) to study discharge for AEs (up to 15 days); Day 1 to 30 days after last dose of study treatment for SAEs (up to 44 days). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Group 1: Total—0/14 (0%)6/14 (42.9%)
Group 1: Daclatasvir (60 mg)—0/14 (0%)1/14 (7.1%)
Group 1: Daclatasvir (30 mg) + Darunavir/Ritonavir—0/14 (0%)6/14 (42.9%)
Group 2: Total—0/14 (0%)8/14 (57.1%)
Group 2: Daclatasvir (60 mg)—0/14 (0%)3/14 (21.4%)
Group 2: Daclatasvir (30 mg) + Lopinavir/Ritonavir—0/14 (0%)8/14 (57.1%)
Most frequent other events
Showing 10 of 14
Most frequent other events
EventGroup 1: TotalGroup 1: Daclatasvir (60 mg)Group 1: Daclatasvir (30 mg) + Darunavir/RitonavirGroup 2: TotalGroup 2: Daclatasvir (60 mg)Group 2: Daclatasvir (30 mg) + Lopinavir/Ritonavir
DiarrhoeaGastrointestinal disorders2/140/142/145/140/145/14
NauseaGastrointestinal disorders0/140/140/144/142/142/14
HeadacheNervous system disorders1/140/141/143/142/141/14
Drug eruptionSkin and subcutaneous tissue disorders2/140/142/141/140/141/14
Decreased appetiteMetabolism and nutrition disorders0/140/140/142/141/141/14
Electrocardiogram PR prolongationInvestigations1/140/141/140/140/140/14
Chest discomfortGeneral disorders0/140/140/141/140/141/14
Soft tissue injuryInjury, poisoning and procedural complications0/140/140/141/140/141/14
CoughRespiratory, thoracic and mediastinal disorders0/140/140/141/141/140/14
PresyncopeNervous system disorders0/140/140/141/140/141/14

Baseline characteristics

Age, Customized
Age, Customized(participants)Daclatasvir + Darunavir/RitonavirDaclatasvir + Lopinavir/RitonavirTotal
Between 18 and 65 years141428
Sex: Female, Male
Sex: Female, Male(Participants)Daclatasvir + Darunavir/RitonavirDaclatasvir + Lopinavir/RitonavirTotal
Female549
Male91019
08

Study locations

1 site
  • Healthcare Discoveries, Llc D/B/A Icon Development Solutions
    San Antonio, Texas 78209, United States
09

References and documents

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2014, a primary completion of Jul 2014 and a completion of Jul 2014. It does not say whether these dates are actual or estimated.

Results were first posted in Nov 2015, 1 year 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 6, 2014
First posted
Jun 9, 2014
Start
Jun 2014
Primary completionActual
Jul 2014
CompletionActual
Jul 2014
Results first posted
Nov 30, 2015
Last update
Nov 30, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 30, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02159352
Responsible party
Sponsor
First posted
Jun 9, 2014
Start date
Jun 2014
Primary completion
Jul 2014
Completion
Jul 2014
Results posted
Nov 30, 2015
Last update
Nov 30, 2015

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Daclatasvir · Darunavir · Ritonavir

Start the discussion